Details of the Drug

General Information of Drug (ID: DMOMK1V)

Drug Name
Halofantrine
Synonyms
Halfan; Halofantrino; HALOFANTRINE HYDROCHLORIDE; Halofantrine HCl; Halofantrine Hydrochloride [USAN]; Halofantrine [USAN]; Halofantrino [Spanish]; WR 171669; Dl-WR 171669; Halfan (TN); Halofantrine hydrochloride (USAN); WR 171,699; WR-171669; WR-171699; SK&F-102866; WR-171,669; (+-)-Halofantrine hydrochloride; (1)-Halofantrine; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrene-methanol; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenathrenemethanol; 1,3-Dichloro-6-trifluoromethyl-9-(3-(dibutylamino)-1-hydroxypropyl)phenanthrene HCl; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)phenanthren-1-methanol hydrochloride; 1-(1,3-Dichloro-6-trifluoromethyl-9-phenanthryl)-3-(di-n-butylamino)propanol hydrochloride; 1-(1,3-dichloro-6-trifluoromethyl-9-phenanthryl)-3-di(n-butyl)aminopropanol HCl; 3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol hydrochloride; 9-(3-(dibutylamino)-1-hydroxypropyl)-1,3-dichloro-6-(trifluoromethyl)phenanthrene hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-(1); 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-, hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-,hydrochloride
Indication
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Approved [1]
Therapeutic Class
Antimalarials
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 500.4
Topological Polar Surface Area (xlogp) 8.6
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 6 - 10 days [2]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 49.95641 micromolar/kg/day [4]
Chemical Identifiers
Formula
C26H30Cl2F3NO
IUPAC Name
3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol
Canonical SMILES
CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O
InChI
InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3
InChIKey
FOHHNHSLJDZUGQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
37393
ChEBI ID
CHEBI:94392
CAS Number
69756-53-2
DrugBank ID
DB01218
TTD ID
D07MVK
VARIDT ID
DR00770
INTEDE ID
DR0799

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calmodulin (CALM) TTV3NH6 CALM1_HUMAN; CALM2_HUMAN; CALM3_HUMAN Modulator [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [8]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Malaria
ICD Disease Classification 1F40-1F45
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Calmodulin (CALM) DTT CALM 6.44E-01 0.09 0.15
Calmodulin (CALM) DTT CALM 5.89E-01 -3.28E-04 -1.09E-03
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.94E-01 -1.03E-01 -3.08E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 7.37E-02 9.49E-02 8.07E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 1.17E-01 -3.87E-02 -2.23E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.74E-01 7.48E-03 1.37E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 2.59E-01 6.29E-02 3.14E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 4.84E-01 -8.38E-02 -8.46E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 4.66E-01 4.25E-02 1.20E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 4.75E-01 5.15E-02 3.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Halofantrine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Halofantrine and Lumefantrine. Malaria [1F40-1F45] [48]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Halofantrine and Hydroxychloroquine. Malaria [1F40-1F45] [49]
Coadministration of a Drug Treating the Disease Different from Halofantrine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Halofantrine and Ivosidenib. Acute myeloid leukaemia [2A60] [50]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Halofantrine and Midostaurin. Acute myeloid leukaemia [2A60] [49]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Halofantrine and Arn-509. Acute myeloid leukaemia [2A60] [49]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Halofantrine and Gilteritinib. Acute myeloid leukaemia [2A60] [49]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Halofantrine and Oliceridine. Acute pain [MG31] [50]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Halofantrine and Ivabradine. Angina pectoris [BA40] [51]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Halofantrine and Dronedarone. Angina pectoris [BA40] [52]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Halofantrine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [49]
Posaconazole DMUL5EW Major Decreased metabolism of Halofantrine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [49]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Halofantrine and Levalbuterol. Asthma [CA23] [53]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Halofantrine and Pirbuterol. Asthma [CA23] [53]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Halofantrine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [49]
Dalfopristin DM4LTKV Major Decreased metabolism of Halofantrine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [54]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Halofantrine and Retigabine. Behcet disease [4A62] [50]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Halofantrine caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [55]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Halofantrine and Eribulin. Breast cancer [2C60-2C6Y] [49]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Halofantrine and Lapatinib. Breast cancer [2C60-2C6Y] [49]
Tucatinib DMBESUA Major Decreased metabolism of Halofantrine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Halofantrine and Bosutinib. Breast cancer [2C60-2C6Y] [49]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Halofantrine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [50]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Halofantrine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [56]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Halofantrine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [53]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Halofantrine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [56]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Halofantrine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [56]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Halofantrine and Sevoflurane. Corneal disease [9A76-9A78] [49]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Halofantrine and Pasireotide. Cushing syndrome [5A70] [49]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Halofantrine and Osilodrostat. Cushing syndrome [5A70] [50]
Ivacaftor DMZC1HS Major Decreased metabolism of Halofantrine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [49]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Halofantrine and Clomipramine. Depression [6A70-6A7Z] [49]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Halofantrine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [49]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Halofantrine and Ingrezza. Dystonic disorder [8A02] [49]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Halofantrine and Solifenacin. Functional bladder disorder [GC50] [49]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Halofantrine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [49]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Halofantrine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Halofantrine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [50]
Cobicistat DM6L4H2 Major Decreased metabolism of Halofantrine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Halofantrine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [49]
Etravirine DMGV8QU Moderate Increased metabolism of Halofantrine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Halofantrine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [49]
Darunavir DMN3GCH Major Decreased metabolism of Halofantrine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Halofantrine and Polyethylene glycol. Irritable bowel syndrome [DD91] [58]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Halofantrine and Crizotinib. Lung cancer [2C25] [49]
Brigatinib DM7W94S Moderate Increased metabolism of Halofantrine caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [59]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Halofantrine and Ceritinib. Lung cancer [2C25] [49]
PF-06463922 DMKM7EW Moderate Increased metabolism of Halofantrine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [60]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Halofantrine and Osimertinib. Lung cancer [2C25] [49]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Halofantrine and Selpercatinib. Lung cancer [2C25] [50]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Halofantrine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [49]
Idelalisib DM602WT Major Decreased metabolism of Halofantrine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [49]
IPI-145 DMWA24P Major Decreased metabolism of Halofantrine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [54]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Halofantrine and Vemurafenib. Melanoma [2C30] [49]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Halofantrine and LGX818. Melanoma [2C30] [49]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Halofantrine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [51]
Danazol DML8KTN Major Decreased metabolism of Halofantrine caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [49]
Exjade DMHPRWG Moderate Decreased metabolism of Halofantrine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [61]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Halofantrine and Panobinostat. Multiple myeloma [2A83] [49]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Halofantrine and Siponimod. Multiple sclerosis [8A40] [50]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Halofantrine and Fingolimod. Multiple sclerosis [8A40] [52]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Halofantrine and Ozanimod. Multiple sclerosis [8A40] [49]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Halofantrine and Romidepsin. Mycosis fungoides [2B01] [50]
Fedratinib DM4ZBK6 Major Decreased metabolism of Halofantrine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [49]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Halofantrine and Nilotinib. Myeloproliferative neoplasm [2A20] [49]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Halofantrine and Dasatinib. Myeloproliferative neoplasm [2A20] [49]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Halofantrine and Entrectinib. Non-small cell lung cancer [2C25] [50]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Halofantrine and Lofexidine. Opioid use disorder [6C43] [49]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Halofantrine and Rucaparib. Ovarian cancer [2C73] [49]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Halofantrine and Triclabendazole. Parasitic worm infestation [1F90] [50]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Halofantrine and Pimavanserin. Parkinsonism [8A00] [49]
Abametapir DM2RX0I Moderate Decreased metabolism of Halofantrine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [62]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Halofantrine and Macimorelin. Pituitary gland disorder [5A60-5A61] [63]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Halofantrine and Lefamulin. Pneumonia [CA40] [50]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Halofantrine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [54]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Halofantrine and Degarelix. Prostate cancer [2C82] [49]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Halofantrine and ABIRATERONE. Prostate cancer [2C82] [49]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Halofantrine and Enzalutamide. Prostate cancer [2C82] [49]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Halofantrine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [64]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Halofantrine and Quetiapine. Schizophrenia [6A20] [49]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Halofantrine caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [50]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Halofantrine and Iloperidone. Schizophrenia [6A20] [49]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Halofantrine and Paliperidone. Schizophrenia [6A20] [49]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Halofantrine and Amisulpride. Schizophrenia [6A20] [49]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Halofantrine and Asenapine. Schizophrenia [6A20] [49]
Voxelotor DMCS6M5 Major Decreased metabolism of Halofantrine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [54]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Halofantrine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [51]
Larotrectinib DM26CQR Major Decreased metabolism of Halofantrine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [54]
Armodafinil DMGB035 Minor Increased metabolism of Halofantrine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [65]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Halofantrine and LEE011. Solid tumour/cancer [2A00-2F9Z] [49]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Halofantrine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [49]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Halofantrine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [49]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Halofantrine and Pitolisant. Somnolence [MG42] [49]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Halofantrine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [49]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Halofantrine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [66]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Halofantrine and Lenvatinib. Thyroid cancer [2D10] [49]
⏷ Show the Full List of 93 DDI Information of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020250.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther. 2002 Nov;72(5):514-23.
7 Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998 Mar;45(3):315-7.
8 Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol. 1999 Apr;51(4):419-26.
9 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
19 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
20 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
21 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
22 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
23 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
24 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
25 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
26 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
27 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
28 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
29 Drug Interactions Flockhart Table
30 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
31 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
32 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
33 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
34 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
35 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
36 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
37 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
38 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
39 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
40 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
41 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
42 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
43 Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5.
44 Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6.
45 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
46 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
47 Calmidazolium evokes high calcium fluctuations in Plasmodium falciparum. Cell Signal. 2016 Mar;28(3):125-135.
48 Giao PT, de Vries PJ "Pharmacokinetic interactions of antimalarial agents." Clin Pharmacokinet 40 (2001): 343-73. [PMID: 11432537]
49 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
50 Cerner Multum, Inc. "Australian Product Information.".
51 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
52 Canadian Pharmacists Association.
53 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
54 Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C "Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine." Clin Pharmacol Ther 72 (2002): 514-23. [PMID: 12426515]
55 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
56 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
57 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
58 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
59 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
60 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
61 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
62 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
63 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
64 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
65 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
66 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.